Relapsed Solid Tumors
8
4
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
KSX01-TCRT Injection Project in Solid Tumors
KSH01-TCRT Solid Tumors
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
Pharmacokinetic Studies Participation Survey